Webinar

The Evolution of Liver Cancer Market in 2024

On Demand
Duration: 60 Minutes
Original Date: July 17, 2024

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Join Bloomberg virtually on July 17 as we discuss the current landscape of liver cancer treatment with Dr. Leslie Oleksowicz, who directs a specialized multi-disciplinary hepatocellular cancer program at the University of Cincinnati medical center, including potential advances in the treatment of early stage disease after trial successes from AstraZeneca and Roche and the evolving first line landscape.

Speakers

Max Nisen

Analyst

Bloomberg Intelligence

Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.

Leslie Oleksowicz

Director of G.I. Oncology

Member HCC Center of Excellence

Dr. Leslie Oleksowicz is a Professor of Medicine and medical oncologist at St. Louis University Cancer Center. She serves as the center's Director of GI Oncology, including a specialized hepatocellular cancer multi-disciplinary program, and of Immuno-Oncology Research. She is a former NCCN panelist for National Cancer Guidelines and has served as principal investigator in over 300 clinical trials.

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.